Literature DB >> 7683590

Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

A Katira1, K A Knox, M Finney, R H Michell, M Wakelam, J Gordon.   

Abstract

IL-4 synergizes with signals delivered through CD40 both for the induction of CD23/Fc epsilon RII expression and for IgE synthesis. Moreover, engagement of CD40 on the B cell surface by MoAb overcomes the ability of interferons, transforming growth factor-beta, or anti-CD19 to inhibit IL-4-dependent change. We now report that occupancy of CD40 relieves potent suppression of IL-4-induced CD23 production by glucocorticoid or the relatively broad-acting kinase inhibitor staurosporine. Interruption of the IL-4 signal was observed with concentrations of staurosporine considered to be selective for protein kinase C (PKC) inhibition (IC50 = 10 nM) but not with genistein or tyrphostins, effective inhibitors of tyrosine kinase activity. On ligation of CD40, staurosporine no longer inhibited the IL-4 signal: at concentrations of between 1 and 20 nM, staurosporine actually increased by as much as 100% the rate of CD23 production stimulated on simultaneous activation through CD40 and IL-4R. Such augmentation was not observed when the more specific PKC inhibitor RO-31-8220 was used; indeed, CD40 engagement was unable to overcome the ability of this inhibitor to block IL-4-promoted CD23 induction (IC50 = 10 microM). Occupancy of CD40 did, however, thwart completely the usual ability of prednisolone to inhibit the IL-4 signal leading to CD23 induction. Activation through CD40 left inhibition of phorbol ester-induced CD23 expression by staurosporine, RO-31-8220, or glucocorticoid unchecked. These findings further highlight the intimate level of cross-talk existing between CD40 and IL-4R on resting B lymphocytes to promote CD23 expression, a phenotypic change which preludes IgE synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683590      PMCID: PMC1554800          DOI: 10.1111/j.1365-2249.1993.tb03403.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

Review 1.  Expression, structure, and function of the CD23 antigen.

Authors:  G Delespesse; U Suter; D Mossalayi; B Bettler; M Sarfati; H Hofstetter; E Kilcherr; P Debre; A Dalloul
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

Review 2.  Regulation of the interleukin 4 signal in human B-lymphocytes.

Authors:  M Finney; R H Michell; S Gillis; J Gordon
Journal:  Biochem Soc Trans       Date:  1991-04       Impact factor: 5.407

3.  Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CDw40).

Authors:  J Cairns; L Flores-Romo; M J Millsum; G R Guy; S Gillis; J A Ledbetter; J Gordon
Journal:  Eur J Immunol       Date:  1988-03       Impact factor: 5.532

4.  Inhibition of interleukin 4-promoted CD23 production in human B lymphocytes by transforming growth factor-beta, interferons or anti-CD19 antibody is overriden on engaging CD40.

Authors:  J Gordon; A Katira; A J Strain; S Gillis
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

5.  Potent selective inhibitors of protein kinase C.

Authors:  P D Davis; C H Hill; E Keech; G Lawton; J S Nixon; A D Sedgwick; J Wadsworth; D Westmacott; S E Wilkinson
Journal:  FEBS Lett       Date:  1989-12-18       Impact factor: 4.124

6.  Epstein-Barr virus and a tumour-promoting phorbol ester use similar mechanisms in the stimulation of human B-cell proliferation.

Authors:  G R Guy; J Gordon
Journal:  Int J Cancer       Date:  1989-04-15       Impact factor: 7.396

7.  Interleukin 4 activates human B lymphocytes via transient inositol lipid hydrolysis and delayed cyclic adenosine monophosphate generation.

Authors:  M Finney; G R Guy; R H Michell; J Gordon; B Dugas; K P Rigley; R E Callard
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

8.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.

Authors:  J Banchereau; P de Paoli; A Vallé; E Garcia; F Rousset
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

9.  CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation signal directly to human B cells for IgE production.

Authors:  K Zhang; E A Clark; A Saxon
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

10.  Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes.

Authors:  C Y Wu; M Sarfati; C Heusser; S Fournier; M Rubio-Trujillo; R Peleman; G Delespesse
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

View more
  3 in total

1.  Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy.

Authors:  N Imami; G A Hardy; M R Nelson; S Morris-Jones; R Al-Shahi; C Antonopoulos; B Gazzard; F M Gotch
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220.

Authors:  J E Tanner; C Alfieri; T A Chatila; F Diaz-Mitoma
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

3.  B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes.

Authors:  H H Wortis; M Teutsch; M Higer; J Zheng; D C Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.